SCHEMBL6729639

SCHEMBL6729639

O=S(=O)(c1cc2cc(Cl)ccc2[nH]1)N1CC(CCO)N(c2ncc(-c3ccncc3)cn2)C(CCO)C1

nearest known ligand 0.42

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
F10 P00742 19/20 0.42
CNR1 P21554 1/20 0.39
KLK1 P06870 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6729876 0.86 F10 (0.54) F10KLK1
SCHEMBL6737336 0.86 F10 (0.53) F10CNR1KLK1
SCHEMBL6729637 0.85 F10 (0.42) F10KLK1
SCHEMBL6731710 0.84 F10 (0.45) F10
SCHEMBL6730980 0.84 F10 (0.55) F10KLK1
SCHEMBL6729623 0.80 F10 (0.44) F10
SCHEMBL6729219 0.77 F10 (0.42) F10CNR1KLK1
SCHEMBL6835099 0.77 F10 (0.52) F10KLK1
SCHEMBL6730350 0.75 PDGFRB (0.31)
SCHEMBL6728636 0.74 F10 (0.58) F10KLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6747023-B1 INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-08 US disclosed
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-29 US disclosed
EP-1104754-A1 NOVEL SULFONYL DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-06-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction F2, CYC1, SULT2A1 F10 19/4885CNR1 162/4885KLK1 3139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.